Methylation of DNA is a common epigenetic modification that plays an important role in the control of gene expression in mammalian cells. This process involves CpG dinucleotide sequences and is catalyzed by DNA-methyltransferase enzymes. Under physiological conditions, methylated CpG sites are only present in DNA sequences typical of bulk chromatin, where the DNA is inaccessible to transcription factors. In contrast, CpG islands of promoter regions are usually unmethylated (with few exceptions such as the genes on the inactive X-chromosome). DNA methylation abnormalities have recently emerged as the most frequent molecular changes in hematopoietic neoplasms.

Leone, G., Teofili, L., Voso, M.t., Lübbert, M. (2002). DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. HAEMATOLOGICA, 87(12), 1324-1341.

DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias

VOSO, MARIA TERESA;
2002-12-01

Abstract

Methylation of DNA is a common epigenetic modification that plays an important role in the control of gene expression in mammalian cells. This process involves CpG dinucleotide sequences and is catalyzed by DNA-methyltransferase enzymes. Under physiological conditions, methylated CpG sites are only present in DNA sequences typical of bulk chromatin, where the DNA is inaccessible to transcription factors. In contrast, CpG islands of promoter regions are usually unmethylated (with few exceptions such as the genes on the inactive X-chromosome). DNA methylation abnormalities have recently emerged as the most frequent molecular changes in hematopoietic neoplasms.
dic-2002
Pubblicato
Rilevanza internazionale
Articolo
Esperti anonimi
Settore MED/15 - MALATTIE DEL SANGUE
English
Antimetabolites, Antineoplastic; Clinical Trials as Topic; DNA Methylation; DNA Modification Methylases; Gene Expression Regulation, Neoplastic; Humans; Neoplasms, Second Primary; Myelodysplastic Syndromes
Leone, G., Teofili, L., Voso, M.t., Lübbert, M. (2002). DNA methylation and demethylating drugs in myelodysplastic syndromes and secondary leukemias. HAEMATOLOGICA, 87(12), 1324-1341.
Leone, G; Teofili, L; Voso, Mt; Lübbert, M
Articolo su rivista
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2108/118372
Citazioni
  • ???jsp.display-item.citation.pmc??? 44
  • Scopus 163
  • ???jsp.display-item.citation.isi??? 132
social impact